Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory securities investigation

Pomerantz Investigates Emergent BioSolutions Securities Claims

Analysis based on 12 articles · First reported Aug 25, 2026 · Last updated Sep 10, 2026

Sentiment
-20
Attention
2
Articles
12
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The investigation adds legal and reputational pressure on Emergent BioSolutions after its sharp guidance cut and impairment charge, keeping downside risk elevated for the stock. Broader market impact is limited, as the matter is company-specific and does not signal systemic issues for the pharmaceutical sector.

pharmaceuticals legal services

Pomerantz LLP LLP announced it is investigating claims on behalf of investors of Emergent BioSolutions Inc. concerning whether the company and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices. The investigation follows Emergent's August 5, 2026 report of results for the quarter ended June 30, 2026, in which the company announced a $191.3 million non-cash impairment charge on the NARCAN asset group, driving a GAAP net loss of $180.2 million, and cut full year revenue guidance by approximately 10.8% at the midpoint. Management attributed the results to increased competitive intensity with implications for its near to medium term outlook and the book value of the NARCAN asset group. On this news, Emergent's stock price fell $2.23 per share, or 29.58%, to close at $5.31 per share on August 6, 2026. Pomerantz LLP, a firm known for securities class actions, is soliciting affected investors to contact it regarding potential claims. The investigation is at an early stage and no lawsuit has been filed.

90 Emergent BioSolutions reported quarterly results
80 Emergent BioSolutions cut revenue guidance
60 Pomerantz LLP investigates claims Emergent BioSolutions
stock
Emergent is the subject of the securities fraud investigation and the company whose impairment charge, guidance cut, and 29.58% stock drop triggered it. The probe raises the risk of litigation costs and further reputational damage.
Importance 95.0 Sentiment -60.0
priv
Pomerantz LLP is the law firm conducting the investigation into Emergent on behalf of investors, a routine step before any potential class action. The probe generates legal fees and publicity for the firm.
Importance 70.0 Sentiment 0.0
exch
The NYSE is the listing venue where Emergent shares trade and where the 29.58% price decline occurred. The event has no material effect on the exchange itself.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.